AU3614493A - Non-toxic lipid vaccine formulations - Google Patents

Non-toxic lipid vaccine formulations

Info

Publication number
AU3614493A
AU3614493A AU36144/93A AU3614493A AU3614493A AU 3614493 A AU3614493 A AU 3614493A AU 36144/93 A AU36144/93 A AU 36144/93A AU 3614493 A AU3614493 A AU 3614493A AU 3614493 A AU3614493 A AU 3614493A
Authority
AU
Australia
Prior art keywords
vaccine formulations
toxic lipid
lipid vaccine
toxic
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36144/93A
Inventor
Gail L. Barchfeld
Gary Ott
Robert Ralston
Mark Selby
Richard Spaete
Gary Van Nest
Christopher Walker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU3614493A publication Critical patent/AU3614493A/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU36144/93A 1992-02-04 1993-02-04 Non-toxic lipid vaccine formulations Abandoned AU3614493A (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US885905 1986-07-15
US83061292A 1992-02-04 1992-02-04
US830612 1992-02-04
US88590592A 1992-05-18 1992-05-18
US94263992A 1992-09-09 1992-09-09
US942639 1992-09-09

Publications (1)

Publication Number Publication Date
AU3614493A true AU3614493A (en) 1993-09-01

Family

ID=27420220

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36144/93A Abandoned AU3614493A (en) 1992-02-04 1993-02-04 Non-toxic lipid vaccine formulations

Country Status (2)

Country Link
AU (1) AU3614493A (en)
WO (1) WO1993014744A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
EP0734251B1 (en) * 1993-12-17 2009-10-14 Novavax, Inc. Method of transmitting a biologically active material to a cell
FR2726764B1 (en) * 1994-11-14 1997-01-31 Pasteur Merieux Serums Vacc ADJUVANT FOR VACCINE COMPOSITION
EP0902682A2 (en) 1996-05-08 1999-03-24 Nika Health Products Limited Cationic virosomes as transfer system for genetic material
CU23313A1 (en) * 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia MÃ0 / 00 METHOD OF OBTAINING COCLEAR STRUCTURES VACCINAL COMPOSITIONS AND ADJUSTS BASED ON COCLEAR STRUCTURES AND THEIR INTERMEDIARIES
WO2005041932A2 (en) * 2003-11-03 2005-05-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for selecting cationic or anionic liposomes for treatment of a mucosa membrane, and kit comprising the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen

Also Published As

Publication number Publication date
WO1993014744A1 (en) 1993-08-05

Similar Documents

Publication Publication Date Title
IL101290A0 (en) Vaccine formulations
AU8131191A (en) Sustained release formulations
AU1802492A (en) New aqueous formulations
AU8554691A (en) Improved formulations
AU1218892A (en) Pharmaceutical aerosol formulations
AU3049392A (en) Underarm formulations containing alkylmethylsiloxanes
GB9207832D0 (en) Formulations
AU8289891A (en) Improved antiperspirant formulations
AU8039591A (en) Gel formulations
AU8130391A (en) Solid formulations
GB9118830D0 (en) Medical aerosol formulations
AU3154395A (en) Contraceptive vaccine
AU1247192A (en) Steroid formulations
AU2769595A (en) Contraceptive vaccine
GB9214390D0 (en) Formulations
AU3614493A (en) Non-toxic lipid vaccine formulations
IL117670A0 (en) Low dose ridogrel formulations
AU4450696A (en) Enhanced immunogenic vaccine
GB9201639D0 (en) Pharmaceutical formulations
AU4970193A (en) IPNV vaccine
AU641509B2 (en) Gemfibrozil formulations
AU634086B2 (en) Gemfibrozil formulations
AU1851392A (en) Ccv vaccine
AU663388B2 (en) Sustained release formulations
AU1001397A (en) Sustained release capsule and formulations